Search Results

By Chau T. Dang, MD, Pedram Razavi, MD, PhD, Sarat Chandarlapaty, MD, PhD, and Shanu Modi, MD  / May 25, 2019

Trastuzumab Emtansine in Treatment of Residual Breast Cancer After Neoadjuvant Therapy: Who Will Benefit?

The discovery of trastuzumab has been revolutionary in the treatment of HER2-positive breast cancer, both in the metastatic and early-stage settings.1-6 This cannot be disputed. In the early-stage setting, the addition of trastuzumab to standard chemotherapy has led to a 50% gain in...